Jazz Pharmaceuticals (JAZZ) Return on Capital Employed (2011 - 2026)

Jazz Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 0.4% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 603.0% year-over-year to 0.4%; the TTM figure through Mar 2026 stood at 0.4% (down 603.0% YoY), while the FY2025 annual figure was 4.48%, down 1120.0% from the prior year.
• Return on Capital Employed was 0.4% for Q1 2026 at Jazz Pharmaceuticals, up from 4.64% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 6.46% in Q4 2024 to a low of 5.57% in Q3 2025.
• Historically, Return on Capital Employed has averaged 1.67% across 5 years, with a median of 2.0% in 2023.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 660 bps in 2023, then sank 1158 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 0.68% in 2022, then surged by 975 bps to 5.93% in 2023, then advanced by 9 bps to 6.46% in 2024, then sank by 172 bps to 4.64% in 2025, then jumped by 91 bps to 0.4% in 2026.
• The last three Return on Capital Employed figures came in at 0.4% (Q1 2026), 4.64% (Q4 2025), and 5.57% (Q3 2025), per Business Quant data.